The article discusses a market research report forecasting growth of the TCR-based antibody market up to 2032. It highlights key players like Immunocore, Adaptimmune, Gilead Sciences, and Takara Bio, segments the market by product type (Monospecific, Bispecific, Multispecific TCR) and application (Cancer, Infectious Disease, Autoimmune Disorders), and provides regional analysis across North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, and the Middle East/Africa. The report includes competitive strategies, market trends, and investment opportunities.

DelveInsight's report highlights 20+ biotech and pharmaceutical companies developing HER2-positive gastric cancer therapies, including clinical trials for drugs like rilvegostomig, trastuzumab deruxtecan, and SHR-A1811. The report covers pipeline drugs across phases I-III, therapeutic mechanisms, and collaborations in oncology research.

Australian researchers at the Peter MacCallum Cancer Center are developing a CRISPR-edited CAR T-cell therapy for solid tumors, using gene promoters NR4A2 and RGS16 to enhance cytokine delivery and target cancer cells more precisely. The therapy aims to improve efficacy against breast, ovarian, and other solid tumors, with preclinical trials suggesting near-100% cure rates. The team plans first-in-human trials within five years, addressing challenges like tumor microenvironment suppression and cytokine toxicity. Regulatory and cost hurdles, including CRISPR-editing scrutiny, remain critical barriers to clinical adoption.

The Adoptive Cell Therapy Market is projected to experience transformative growth between 2025 and 2032, driven by advancements in cancer immunotherapy and next-generation gene-modified cell platforms. A comprehensive industry analysis by Worldwide Market Reports highlights key insights into evolving technologies, regulatory milestones, and global expansion strategies, offering actionable intelligence for healthcare, biotech, and oncology sectors.

Mizuho downgraded Adaptimmune (ADAP) from Outperform to Neutral, reducing its price target from $1.50 to $0.50. The firm cited financial viability and long-term stability concerns, including challenges in launching Tecelra and maintaining cash flow. Adaptimmune reported $4M in Q1 2025 sales from Tecelra, with revenue guidance of $35M–$45M for the year. The company has 28 authorized treatment centers, a 100% manufacturing success rate, and a peak sales projection of $400M. However, it faces a going concern warning due to less than 12 months of cash runway.